RT - Journal
TY - JOUR
A1 - Akl, Ghada
A1 - Shoeib, Sabry
A1 - Abdelhafez, Mohamed
A1 - Abdelhamid, Alaa
A1 - Ali, Ali
A1 - Abdelmohsen, Essam
T1 - Autologous bone marrow transplantation for diffuse large B-cell lymphoma in Egypt: a two-center experience
YR - 2021/1/1
JF - Menoufia Medical Journal
JO - Menoufia Med J
SP - 93
OP - 97
VO - 34
IS - 1
UL - http://www.mmj.eg.net/article.asp?issn=1110-2098;year=2021;volume=34;issue=1;spage=93;epage=97;aulast=Akl;t=5
DO - 10.4103/mmj.mmj_106_19
N2 -
Objective
The aim of this work was to study the outcome of autologous bone marrow transplantation in diffuse large B-cell lymphoma (DLBCL) according to the experience of two centers, Naser Institute and Sheikh Zayed centers.
Background
Treatment for patients with DLBCL is based on the international prognostic index score and age. Autologous stem-cell transplantation (ASCT) is actually recommended in young patients who did not achieve complete remission after first-line chemotherapy.
Patients and methods
This retrospective case series study included the files of 191 patients who were diagnosed as having DLBCL according to the 2008 WHO classification of lymphoma in Naser Institute and Sheikh Zayed hematology units in the period from 2012 to 2018. The patients were classified into two groups. Group I: patients with DLBCL and received chemotherapy only, Group II: patients with DLBCL and received chemotherapy and then high-dose chemotherapy followed by ASCT (HDC).
Results
The data we had shown that there is no significant statistical difference between the studied groups as regards age and sex. The mean age was 40.34 years (±11.620) in patients with DLBCL and received chemotherapy only while in patients with DLBCL and received chemotherapy then HDC/ASCT was 42.66 years (±11.554). The 5-year overall survival in patients with chemotherapy only is not statistically significant compared with patients with chemotherapy and then HDC/ASCT (P = 0.202).
Conclusion
On the basis of our results, we can conclude that the outcome of HDC/ASCT in patients with DLBCL is nearly equal to the outcome of chemotherapy alone.
ER -